Troy Wilson is the former CEO of San Diego-based Intellikine, which was acquired by Takeda Pharmaceuticals in 2011. Dr. Wilson was formerly co-founder and Chief Business Officer at Ambrx, a biotechnology company focused on the optimization of protein-based medicines using non-natural amino acids as well as a co-founder of Wildcat Discovery Technologies. He previously served as Vice President, Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego where he played a key role in the creation and launch of several spinout companies. Dr. Wilson received his Ph.D. in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.
Index Ventures made news recently when it announced a new €150 million fund to invest in early-stage, life science companies. With many venture firms scaling back or exiting the business entirely, any... Read more »
Sanofi-Aventis and Merck KGaA announced recently they are teaming up to test new cancer drugs in combination, joining a growing trend among drug makers to combine different cancer therapies in early-stage clinical studies.... Read more »
